Slides
Page 1
ION EXCHANGE Refreshing the Planet Earnings Presentation Q1 - FY27 CLE
Page 2
62 + YEARS OF EXPERTISE OPERATIONS IN 50 + COUNTRIES 360° TOTAL WATER & ENVIRONMENT MANAGEMENT WORLD CLASS MANUFACTURING FACILITIES ONE OF ASIA’S LARGEST SERVICE NETWORKS SERVING INDUSTRIES, INSTITUTIONS, HOMES & COMMUNITIES GLOBAL ASSEMBLY HUBS IN UAE, SAUDI ARABIA, SOUTH AFRICA, INDONESIA & BANGLADESH ADVANCED R&D CENTRES IN INDIA COMMITTED TO SUSTAINABILITY Company Snapshot 200,000 + INSTALLATIONS WORLD-WIDE 3,000 + CORE INDUSTRY PROJECTS EXPORTS ACROSS CONTINENTS
Page 3
Total Water & Environment Management Solutions Management of Process Water Specialty Resins / Adsorbents / Membranes / Chemicals / Enzymes for Purification & Concentration Industrial Wastewater Treatment Recycle & Zero Liquid Discharge Drinking Water Treatment Sewage Treatment, Tertiary Sewage Recycle, Sludge Management Pretreatment Process Water Treatment – Ion Exchange & Membrane Based
Page 4
ZERO LIQUID DISCHARGE Leaders in Resins, Membranes & Chemicals, with a Unique End-to-End Portfolio Spanning Solutions, Digital & Services PROCESS WATER TREATMENT HIGH PURITY WATER ULTRA PURE WATER INDUSTRIAL WASTEWATER TREATMENT 1 2 3 4 5 7 8 DRINKING WATER SOLUTIONS SOURCE WATER & PRETREATMENT MUNICIPAL & SEWAGE TREATMENT 6 Capabilities RESINS MEMBRANES CHEMICALS SOLUTIONS SERVICES DIGITAL
Page 5
50+ COUNTRIES SERVED 30% INTERNATIONAL REVENUE SHARE 14 GLOBAL MANUFACTURING FACILITIES & ASSEMBLY CENTRES GLOBAL INSTALLATIONS 200,000+ Our Global Offices Global Presence
Page 6
Ankleshwar, Gujarat Resins Manufacturing - Exports Verna, Goa Centre of Membrane Excellence Roha, Maharashtra Non-Solvent Resins Patancheru, Telangana Chemicals Manufacturing Portugal MAPRIL, Manufacturing Facility Saudi Arabia Chemical Blending Facility Global Manufacturing Facilities
Page 7
Hosur, Tamil Nadu Standard Systems Assembly Wada, Maharashtra Standard Systems Assembly UAE Assembly Unit, ICV Certified Facility Indonesia Assembly and Testing Center Bangladesh Fabrication Unit & Assembly Centre South Africa Manufacturing Facility Palaspe, Maharashtra Large System Assembly Verna, Goa Standard Membrane Systems Global Manufacturing Facilities
Page 8
Ion Exchange (India) Ltd. Current Reporting Treatment Solutions Industrial Products Lifecycle Services Specialty Chemicals Consumer Products Current vs New Reporting Segments New Reporting Institutional Engineering Chemicals Consumer Products
Page 9
CONSUMER PRODUCTS INDUSTRIAL PRODUCTS LIFECYCLE SERVICES TREATMENT SOLUTIONS SPECIALTY CHEMICALS New Reporting Segments ▪ Water Treatment ▪ Ultra Pure Water ▪ High Purity Water ▪ Desalination ▪ Wastewater Treatment & Recycle ▪ Zero Liquid Discharge (ZLD) ▪ PFAS ▪ Standard Water Treatment Solutions ▪ Membranes (RO, UF, NF, MBR) ▪ Institutional Water Treatment Products ▪ Operations & Maintenance (O&M) ▪ Rehabilitation & Modification ▪ Spares, Services & Consumables ▪ BOO/BOOT/WaaS ▪ Rentals ▪ Audits ▪ Remote Monitoring ▪ Water Treatment Chemicals ▪ Utility Chemicals ▪ Process Chemicals ▪ Membrane Chemicals ▪ Polymers ▪ Resins ▪ Industrial ▪ Process ▪ Pharma ▪ Home Water Solutions ▪ Community Water Treatment Solutions ▪ Wellness ▪ Hydrogen Water ▪ Alkaline Water 1 2 3 4 5
Page 10
Financial Overview Q1-FY27
Page 11
Q1-FY27 Financial Highlights Q1-FY27 Performance (Standalone) Q1-FY27 Performance (Consolidated) Engineering projects^ ~ INR 21,820 Mn Total Orderbook ~ INR 24,730 Mn Outstanding Sri Lanka ~ INR 100 Mn Outstanding UP SWSM ~ INR 2,810 Mn Bid Pipeline ~ INR 97,770 Mn Order Book and Pipeline (As on 30 June, 2026) for Treatment Solutions, Industrial Products & Lifecycle Services ^Excluding Sri Lanka Order, UP SWSM. and the recent Contract awarded to the Co – USD 52.83 Mn by Hyundai Engineering & Construction INR 6,356 Mn Operating Income INR 7,005 Mn Operating Income INR 307 Mn Operating EBITDA INR 318 Mn Operating EBITDA 4.83 % Operating EBITDA Margins 4.54 % Operating EBITDA Margins INR 114 Mn Net Profit INR 31 Mn Net Profit 1.79 % PAT Margins 0.44 % PAT Margins INR 0.93 /Share Diluted EPS INR 0.35 /Share Diluted EPS
Page 12
Treatment Solutions 1,839 2,099 168 (174) Q1-FY 26 Q1-FY 27 R E V E NUEE BIT Quarterly Consolidated Segmental Breakup Q1-FY27 Performance Highlights ▪ Revenue growth of 14% ▪ GCC Dispatches resumed .. To pick up momentum ▪ Margins continue to be impacted by legacy projects Future Growth Drivers ▪ Existing backlog liquidation ▪ New emerging segments ▪ Overseas opportunities INR Mn
Page 13
922 1,051 51 125 Q1-FY 26 Q1-FY 27 R E V E NUEE BIT Quarterly Consolidated Segmental Breakup Industrial Products Q1-FY27 Performance Highlights ▪ Revenue growth of 14% ▪ EBIT% up from 5.53% to 11.89% ▪ Strong performance by Standard Water Treatment Solutions and Membranes Future Growth Drivers ▪ Manufacturing expansion for UF Membranes ▪ Expanded capacity for Standard Plants & Systems ▪ Increasing overseas geographical reach INR Mn
Page 14
559 716 59 71 Q1-FY 26 Q1-FY 27 R E VE NUEE BIT Quarterly Consolidated Segmental Breakup Lifecycle Services Q1-FY27 Performance Highlights ▪ Revenue growth of 28% ▪ EBIT% down from 10.55% to 9.92% due to input costs ▪ Focus on O&M and Consumables Future Growth Drivers ▪ Expanding solution offerings ▪ Retrofit business and BOO/BOOT ▪ Digital portfolio and solutions INR Mn
Page 15
1,889 2,297 463 223 Q1-FY 26 Q1-FY 27 R E V E NUEE BIT Quarterly Consolidated Segmental Breakup Specialty Chemicals Q1-FY27 Performance Highlights ▪ Revenue growth of 21% ▪ EBIT down to 9.71% due to geopolitical impact ▪ Higher costs due to Roha facility capex Future Growth Drivers ▪ Increased offtake from Roha Plant ▪ Pharma Resins ▪ Higher share in process chemicals INR Mn
Page 16
843 1,124 (5) (3) Q1-F Y 26 Q1-F Y 27 R E V E NUEE BIT Quarterly Consolidated Segmental Breakup Consumer Products Q1-FY27 Performance Highlights ▪ Revenue Growth of 33% ▪ EBIT slightly up from -0.59% to -0.27% ▪ Strong growth across all key product lines Future Growth Drivers ▪ Growth in the Softener market ▪ Wellness product offerings ▪ New products like OTG INR Mn
Page 17
Quarterly Consolidated Financial Performance INCOME STATEMENT (INR Mn) Q1-FY27 Q1-FY26 Y-o-Y Q4-FY26 Q-o-Q Operating Income 7,005 5,832 20.1% 8,633 (18.9)% Expenses 6,687 5,205 28.5% 8,434 (20.7)% Operating EBITDA 318 627 (49.3)% 199 59.8% Operating EBITDA Margins (%) 4.54% 10.75% (622) bps 2.31% 223 bps Depreciation 218 123 77.2% 196 11.2% Finance Cost 90 26 NA 108 (16.7)% Other Income 60 177 NA 430 NA PBT before Exceptional Items 70 655 (89.3)% 325 (78.5)% Exceptional Items - - NA (1) NA PBT 70 655 (89.3)% 326 (78.5)% Share of Profit of equity accounted Investee 4 4 NA (1) NA Tax 43 175 (75.4)% 82 (47.6)% Profit After Tax 31 484 (93.6)% 243 (87.2)% PAT Margins (%) 0.44% 8.30% (786) bps 2.81% (237) Bps Other Comprehensive Income 3 21 (85.7)% 15 (80.0)% Total Comprehensive Income 34 505 (93.3)% 258 (86.8)% Diluted EPS (INR)# 0.347 4.108 (91.6)% 2.036 (83.0)% #Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140) and shares held by Subsidiary companies: (No of Shares: 43,78,740)
Page 18
Quarterly Standalone Financial Performance #Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Sharehold ing (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140) INCOME STATEMENT (INR Mn) Q1-FY27 Q1-FY26 Y-o-Y Q4-FY26 Q-o-Q Operating Income 6,356 5,178 22.8% 8,139 (21.9)% Expenses 6,049 4,616 31.0% 8,028 (24.7)% Operating EBITDA 307 562 (45.4)% 111 176.6% Operating EBITDA Margins (%) 4.83% 10.85% (602) bps 1.36% 347 bps Depreciation 203 110 84.5% 184 10.3% Finance Cost 82 17 382.4% 101 (18.8)% Other Income 132 195 NA 447 NA PBT before Exceptional Items 154 630 (75.6)% 273 (43.6)% Exceptional Items - - NA - NA PBT 154 630 (75.6)% 273 (43.6)% Tax 40 161 (75.2)% 77 (48.1)% Profit After Tax 114 469 (75.7)% 196 (41.8)% PAT Margins (%) 1.79% 9.06% (727) bps 2.41% (62) bps Other Comprehensive Income (1) - NA (6) NA Total Comprehensive Income 113 469 (75.9)% 190 (40.5)% Diluted EPS (INR)# 0.927 3.814 (75.7)% 1.592 (41.8)%
Page 19
Historic Financial Overview
Page 20
Historical Standalone Financial Performance INCOME STATEMENT (INR Mn) FY23 FY24 FY25 FY26 Q1-FY27 Operating Income 18,923 21,800 25,401 26,789 6,356 Expenses 16,544 19,129 22,549 24,946 6,049 Operating EBITDA 2,379 2,671 2,852 1,843 307 Operating EBITDA Margins (%) 12.57% 12.25% 11.23% 6.88% 4.83% Depreciation 281 330 400 576 203 Finance Cost 90 67 84 205 82 Other Income 450 470 512 950 132 PBT before Exceptional Items 2,458 2,744 2,880 2,012 154 Exceptional Items - - - 145 - PBT 2,458 2,744 2,880 1,867 154 Tax 607 703 735 483 40 Profit After Tax 1,851 2,041 2,145 1,384 114 PAT Margins (%) 9.78% 9.36% 8.44% 5.17% 1.79% Other Comprehensive Income (23) (9) (1) (6) (1) Total Comprehensive Income 1,828 2,032 2,144 1,378 113 Diluted EPS (INR) @ 15.060 16.603 17.447 11.257 0.927 @Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140)
Page 21
PARTICULARS (INR Mn) FY24 FY25 FY26 EQUITIES & LIABILITIES Equity (A) Equity Share Capital 147 147 147 (B) Other Equity 10,597 12,556 13,750 Total Equity 10,744 12,703 13,897 Non-Current Liabilities (A) Financial Liabilities (i) Borrowings 438 1,980 3,082 (ii) Lease Liabilities 87 125 160 (iii) Other financial Liabilities 146 134 124 (B) Provisions 231 173 263 Total Non – Current Liabilities 902 2,412 3,629 Current Liabilities (A) Financial Liabilities (i) Borrowings 34 290 760 (ii) Lease Liabilities 33 46 97 (iii) Trade Payables 6,508 7,346 8,468 (iv) Other Financial Liabilities 589 891 817 (B) Other Current Liabilities 4,383 5,071 4,644 (C) Provisions 72 68 223 (D) Liabilities for current tax (Net) 43 87 69 Total Current Liabilities 11,662 13,799 15,078 GRAND TOTAL - EQUITIES & LIABILITES 23,308 28,914 32,604 PARTICULARS (INR Mn) FY24 FY25 FY26 ASSETS Non-Current Assets (A) Property, Plant and Equipment 2,149 2,414 5,851 (B) Capital Work-in-progress 607 3,170 1,747 (C) Right-of-Use Assets 357 374 428 (D) Other Intangible Assets 125 165 91 (E) Financial Assets (i) Investments 842 855 869 (ii) Trade Receivables 9 7 3 (iii) Loans 220 618 566 (iv) Other Financial Assets 87 91 119 (F) Other Non-Current Assets 242 469 377 (G) Deferred Tax Assets 78 73 140 Total Non – Current Assets 4,716 8,236 10,191 Current Assets (A) Inventories 1,887 2,410 3,856 (B) Financial Assets (i) Investments 5 4 6 (ii) Trade Receivables 9,217 10,988 10,725 (iii) Cash & Cash Equivalents 1,104 1,158 1,411 (iv) Bank Balances 4,246 3,086 1,300 (v) Loans 408 122 99 (vi) Other Financial Assets 142 108 54 (C) Other current assets 1,583 2,802 4,962 Total Current Assets 18,592 20,678 22,413 GRAND TOTAL – ASSETS 23,308 28,914 32,604 Historical Standalone Balance Sheet
Page 22
Historical Consolidated Financial Performance @Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140) and shares held by Subsidiary companies: (No. of Shares- 43,78,740) INCOME STATEMENT (INRMn) FY23 FY24 FY25 FY26 Q1-FY27 Operating Income 19,896 23,479 27,371 29,148 7,005 Expenses 17,346 20,759 24,432 27,046 6,687 Operating EBITDA 2,550 2,720 2,939 2,102 318 Operating EBITDA Margins (%) 12.82% 11.58% 10.74% 7.21% 4.54% Depreciation 291 364 445 626 218 Finance Cost 92 121 135 240 90 Other Income 411 439 486 865 60 PBT before Exceptional Items 2,578 2,674 2,845 2,101 70 Exceptional Items - - - 169 - PBT 2,578 2,674 2,845 1,932 70 Share of Profit of equity accounted Investee 9 15 10 17 4 Tax 637 735 772 517 43 Profit After Tax 1,950 1,954 2,083 1,432 31 PAT Margins (%) 9.80% 8.32% 7.61% 4.91% 0.44% Other Comprehensive Income (17) (3) 1 70 3 Total Comprehensive Income 1,933 1,951 2,084 1,502 34 EPS Diluted (INR) @ 16.595 16.534 17.530 12.034 0.347
Page 23
Historical Consolidated Balance Sheet PARTICULARS (INR Mn) FY24 FY25 FY26 EQUITIES & LIABILITIES Equity (A) Equity Share Capital 142 142 142 (B) Other Equity 10,037 11,937 13,248 Equity attributable to owners 10,179 12,079 13,390 Non Controlling Interest 19 16 13 Total Equity 10,198 12,095 13,403 Non-Current Liabilities (A) Financial Liabilities (i) Borrowings 1,091 2,521 3,576 (ii) Lease liabilities 110 143 171 (iii) Other Financial Liabilities 146 133 125 (B) Provisions 261 208 302 (C) Deferred Tax Liabilities (Net) 93 88 88 (D) Other Non-Current Liabilities 4 - - Total Non – Current Liabilities 1,705 3,093 4,262 Current Liabilities (A) Financial Liabilities (i) Borrowings 285 510 968 (ii) Lease liabilities 38 53 107 (iii) Trade Payables 6,946 7,790 8,997 (iv) Other Financial Liabilities 633 944 880 (B) Other Current Liabilities 4,545 5,199 4,817 (C) Provisions 84 78 280 (D) Liabilities for current tax (Net) 60 107 85 Total Current Liabilities 12,591 14,681 16,134 GRAND TOTAL - EQUITIES & LIABILITES 24,494 29,869 33,799 PARTICULARS (INR Mn) FY24 FY25 FY26 ASSETS Non-Current Assets (A) Property, Plant and Equipment 3,018 3,280 6,853 (B) Capital Work-in-progress 607 3,178 1,747 (C) Right-of-Use Assets 383 394 444 (D) Other Intangible Assets 162 203 140 (E) Goodwill 102 102 102 (F) Investment accounted using Equity Method 62 68 85 (G) Financial Assets (i) Investments 55 59 68 (ii) Trade Receivables 42 7 3 (iii) Other Financial Assets 158 154 175 (H) Deferred Tax Assets (Net) 85 77 144 (I) Other Non-Current Assets 308 536 445 (J) Non-Current Tax Assets 6 8 26 Total Non – Current Assets 4,988 8,066 10,232 Current Assets (A) Inventories 2,365 2,990 4,414 (B) Financial Assets (i) Investments 5 4 6 (ii) Trade Receivables 9,348 11,074 10,747 (iii) Cash & Cash Equivalents 1,536 1,493 1,846 (iv) Bank Balances 4,343 3,165 1,341 (v) Loans 79 53 66 (vi) Other Financial Assets 160 133 79 (C) Current Tax Assets (Net) 11 5 22 (D) Other Current Assets 1,659 2,886 5,046 Total Current Assets 19,506 21,803 23,567 GRAND TOTAL – ASSETS 24,494 29,869 33,799
Page 24
Revenues (INR Mn) Consolidated Historical Financial Performance Summary ▪ Growth till FY25 driven by strong backlog ▪ FY26 growth impacted by geopolitical challenges ▪ Chemicals and CPD Segments growing strongly Future Actions ▪ Treatment Solutions growth from overseas backlog ▪ Specialty Segment growth from Roha Plant ▪ Continued growth in Consumer Products 19,896 23,479 27,371 29,148 FY23 FY24 FY25 FY26
Page 25
Operating EBITDA (INR Mn) Consolidated Historical Financial Performance Summary ▪ Impact of Higher Cost profile in certain EPC contracts ▪ Slowed execution of UP Contract ▪ Roha Facility Costs consequent to plant commissioning in FY 26 ▪ Impact of West Asia crisis ▪ Investment in overseas Geographies Future Actions ▪ Strengthening presence in International Markets ▪ Ramp up of Roha volumes ▪ Growth in Industrial Products and Lifecycle Services ▪ Profitability of Consumer Products 2,550 2,720 2,939 2,102 12.82% 11.58% 10.74% 7.21% FY23 FY24 FY25 FY26 EBITDA EBITDA Margins
Page 26
PAT (INR Mn) Consolidated Historical Financial Performance 1,950 1,954 2,083 1432 9.80% 8.32% 7.61% 4.91% FY23 FY24 FY25 FY26 PAT PAT Margins Summary ▪ Impact of Higher Cost profile in certain EPC contracts ▪ Slowed execution of UP Contract ▪ Roha Facility Costs consequent to plant commissioning in FY 26 ▪ Impact of West Asia crisis Future Actions ▪ Strengthening presence in International Markets ▪ Ramp up of Roha volumes ▪ Growth in Industrial Products and Lifecycle Services ▪ Profitability of Consumer Products
Page 27
Net Debt / Equity Consolidated Historical Financial Performance Summary ▪ Ratio within acceptable levels ▪ Roha Capex financed by term loan ▪ Lower Operating EBIDTA in FY 25 and FY 26 Future Actions ▪ Revenue generation from Roha facility ▪ Higher share of Industrial Products, Life cycle Services and Specialty Chemicals ▪ Continue disciplined Capital Allocation (0.6) (0.4) (0.1) 0.01 FY23 FY24 FY25 FY26
Page 28
Return Ratios Consolidated Historical Financial Performance Summary ▪ Roha Plant Capex impact ▪ West Asia crisis impacted gross working capital ▪ Reduced Profitability Future Actions ▪ Higher share of Industrial Products, Life cycle Services and Specialty Chemicals ▪ Continue disciplined Capital Allocation 24.7% 23.3% 21.1% 18.7% 11.2% 32.5% 30.0% 26.9% 22.0% 14.3% FY22 FY23 FY24 FY25 FY26 ROE ROCE ROE = Net Profit/Net worth, ROCE = EBIT/Capital Employed
Page 29
Working Capital Days Consolidated Historical Financial Performance Summary ▪ High proportion in Treatment Solution segment ▪ Impact of West Asia crisis in FY 26 Future Actions ▪ Increased business from Industrial Products, Lifecycle Services and Specialty Chemicals ▪ Increased share of International business ▪ Focus on improving Working Capital Cycle 91 99 94 91 FY23 FY24 FY25 FY26
Page 30
Market Data (Bloomberg – ION IN, Reuters – IONX.BO) S H A R E H O L D I N G P A T T E R N ( A s o n 3 0th J u n e 2 0 2 6 ) -50% -40% -30% -20% -10% 0% 10% Jul-25 Aug-25 Sep-25 Oct-25 Nov-25 Dec-25 Jan-26 Feb-26 Mar-26 Apr-26 May-26 Jun-26 Ion Exchange Sensex 1 Y E A R S H A R E P R I C E M O V E M E N T ( U P T O 3 0t h J u n e 2 0 2 6 ) Promoter 25.4% Mutual Funds 12.5% Alternative Investment Funds, 2.8% Foreign Portfolio Investors, 4.9% Employee Trust, 16.2% Others, 38.2% P R I C EDATA ( A s o n 30 t h J u n e 2026) Face value (INR) 1.00 Market Price (INR) 408.40 52 Week H/L (INR) 580.65 / 312.30 Market Cap (INR Mn) 59,898.64 Equity Shares Outstanding (Mn) 146.67 1 Year Avg. trading volume (‘000) 338.50
Page 31
Disclaimer Ion Exchange (India) Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Ion Exchange (India) Limited (“Company” or “IONEX” ), which are expressed in good faith and in their opinion reasonable, including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company’s business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments. This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from. This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner. Valorem Advisors Disclaimer: Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review. For further details please contact our Investor Relations Representatives: VALOREM ADVISORS Mr. Anuj Sonpal Tel: +91-22-35075100 Email: ion@valoremadvisors.com Investor kit link: https://valoremadvisors.com/ion
Page 32
www.ionexchangeglobal.com
Page 33
Annexures
Page 34
1,732 2,010 183 (183) Q1-FY 26 Q1-FY 27 R E V E NUEE BIT Quarterly Standalone Segmental Breakup Treatment Solutions Q1-FY27 Performance Highlights ▪ Revenue Growth of 16% ▪ Dispatches to GCC resumed .. Pick up going forward ▪ Margins continue to be impacted by few legacy projects Future Growth Drivers ▪ Existing backlog liquidation ▪ New emerging segments ▪ Overseas Opportunities INR Mn
Page 35
885 1,055 46 137 Q1-FY 26 Q1-FY 27 R E V E NUEE BIT Quarterly Standalone Segmental Breakup Industrial Products Q1-FY27 Performance Highlights ▪ Revenue Growth of 19% ▪ EBIT% up from 5.20% to 12.99% ▪ Strong performance by Standard Water Treatment Solutions and Membranes Future Growth Drivers ▪ Manufacturing expansion for UF Membranes ▪ Expanded capacity for Standard Plants & Systems ▪ Increasing overseas geographical reach INR Mn
Page 36
468 587 40 62 Q1-FY 26 Q1-FY 27 R E V E NUEE BIT Quarterly Standalone Segmental Breakup Lifecycle Services Q1-FY27 Performance Highlights ▪ Revenue Growth of 25% ▪ EBIT% increase from 8.55% to 10.56% ▪ Focus on O&M and Consumables Future Growth Drivers ▪ Expanding solution offerings ▪ Retrofit business and BOO/BOOT ▪ Digital portfolio and solutions INR Mn
Page 37
1,471 1,861 411 248 Q1-FY 26 Q1-FY 27 R E V E NUEE BIT Quarterly Standalone Segmental Breakup Specialty Chemicals Q1-FY27 Performance Highlights ▪ Revenue Growth of 27% ▪ EBIT down from 27.94% to 13.33% due to geopolitical impact ▪ Higher depreciation costs due to Roha facility capex Future Growth Drivers ▪ Increased offtake from Roha Plant ▪ Pharma Resins ▪ Higher share in process chemicals INR Mn
Page 38
843 1,124 (6) (4) Q1-F Y 26 Q1-F Y 27 R E V E NUEE BIT Quarterly Standalone Segmental Breakup Consumer Products Q1-FY27 Performance Highlights ▪ Revenue Growth of 33% ▪ EBIT slightly up from -0.71% to -0.36% ▪ Strong growth across all key product lines Future Growth Drivers ▪ Softener growth ▪ Wellness product offerings ▪ New products like OTG INR Mn